Why Journey Medical Corporation’s (DERM) Stock Is Up 5.47%
As of Friday, June 26, Journey Medical Corporation’s DERM share price has surged by 5.47%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Cynthia McLaughlin
Tudor Pop
Michael Rose
Cynthia McLaughlin
| Share Statistics | DERM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $175.4 | $579.1 | 26% |
|
| Shares Out (Mil) | 27.3 | 43.0 | 35% |
|
| Institutional Ownership | 79.4% | 84.3% | 49% |
|
| Float (Mil) | 14.9 | 46.8 | 25% |
|
| Beta | 1.04 | 0.62 | 62% |
|
| Avg Daily Volume (000s) | 145 | 285 | 40% |
|
| Price Change (52-week) |
(16.1%) | 63.8% | 33% |
|
| Growth | DERM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.8% | 6.7% | 45% |
|
| Net Income (5yr) | (32.9%) | (1.4%) | 12% |
|
| EPS (5yr) | (24.2%) | 14.9% | 11 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.0%) | (14.9%) | 42% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | DERM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $65 | $272 | 22% |
|
| Net Income (TTM) (Mil) | ($10) | ($11) | 29% |
|
| EPS (TTM) | ($0.373) | ($0.500) | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($6) | 23% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $23 | $7 | 34% |
|
| Enterprise Value (Q1) (Mil) | $173 | $522 | 25% |
|
| Valuation | DERM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.64 | 2.73 | 81% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | DERM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 65.4% | 65.9% | 77% |
|
| Net Margin | (14.8%) | 0.7% | 18% |
|
| ROA | (10.9%) | (24.6%) | 25% |
|
| ROE | (36.6%) | (19.7%) | 18% |
|
| Liabilities to Assets | 66.3% | 35.5% | 61% |
|
| F-Score | 5 | 3 | 51% |
|
Journey Medical Corporation did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors